As monotherapy or in combination with other glucose-lowering drugs including insulin in the treatment of type 2 DM when diet & exercise alone do not provide adequate glycemic control. Patients with type 2 DM & established CV disease to reduce risk of CV death; used in conjunction with other measures to reduce CV risk in line with current standard of care to prevent CV deaths. Adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 DM to reduce risk of CV death & hospitalization for heart failure; to slow kidney function decline. Adult patients with CKD to reduce risk of kidney disease progression (sustained decline in eGFR, end-stage kidney disease or renal death) or CV death; all-cause hospitalization.

This is not a substitute for consulting your doctor. Seek professional advice if you are experiencing any illness or symptoms.

Type 2 DM Initially 10mg once daily, may be increased to 25mg once daily in patients tolerating starting dose who have eGFR >30 mL/min/1.73 m2 & requiring additional glycemic control. Heart failure & CKD 10mg once daily regardless of renal function.

May be taken with or without food.